Yahoo! Finance: Biotechnology Industry News: Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Want new traffic sources? Download a copy of our complimentary eBook today, and read about sources that most marketers are not aware of. From our sponsors

Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer Aug 27th 2013, 06:30 [PR Newswire] - WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has ...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions